LNKS supply chain intelligence for Linkers Industries Limited: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Linkers Industries Limited (LNKS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RNA | Atrium Therapeutics, Inc. | 80% | Alias reverse search [Linkers]: RNA 10-K (2026-02-23) mentions 'Linkers' in supplier context. Excerpt: multiple cardiac-specific indications. We have multiple early stage research programs ongoing th… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LNKS-DEBT | Debt stack $1.5M | 90% | Market cache reports total debt of $1.5M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ADITYA-BIRLA-GROUP | ADITYA-BIRLA-GROUP | 75% | Wikipedia: Linkers Industries Limited parent = Aditya Birla Group |
| NOVELIS--BR---ALERIS | NOVELIS--BR---ALERIS | 70% | Wikipedia: Novelis <br/> Aleris is subsidiary of Linkers Industries Limited |
| CLRB | CLRB | 62% | Alias reverse search [Linkers]: CLRB 10-K (2026-03-04) mentions 'Linkers' in partner context. Excerpt: payloads, as exemplified by our lead product candidates discussed above. Additional pipeline pro… |
| NRIX | NRIX | 62% | Alias reverse search [Linkers]: NRIX 10-K (2026-01-28) mentions 'Linkers' in partner context. Excerpt: disease efficacy through TPD. This added flexibility enables us to further tap the potential of … |
| COSM | COSM | 62% | Alias reverse search [Linkers]: COSM 10-K (2026-04-15) mentions 'Linkers' in partner context. Excerpt: and finally obesity and weight management. In line with our growth strategy and our focus on int… |
| WHWK | WHWK | 62% | Alias reverse search [Linkers]: WHWK 10-K (2026-03-12) mentions 'Linkers' in partner context. Excerpt: ur product candidates encounter safety or efficacy problems, our product candidates may face cha… |